PMN Correction in Hemorrhagic Ascites
In hemorrhagic ascites, subtract 1 polymorphonuclear leukocyte (PMN) for every 250 red blood cells (RBCs). This is the standard correction factor recommended by major hepatology guidelines to avoid falsely diagnosing spontaneous bacterial peritonitis (SBP) when blood contamination is present 1.
The Correction Formula
When ascitic fluid contains significant RBCs, the PMN count must be adjusted because blood itself contains neutrophils that artificially elevate the ascitic fluid PMN count. The correction is straightforward:
Corrected PMN count = Observed PMN count - (RBC count ÷ 250)
For example, if ascitic fluid shows:
- Observed PMN: 500 cells/mm³
- RBC: 10,000 cells/mm³
- Corrected PMN = 500 - (10,000 ÷ 250) = 500 - 40 = 460 cells/mm³
When to Apply This Correction
This correction should be applied when:
- RBC count ≥10,000 cells/mm³ in ascitic fluid 2
- The ascites appears grossly bloody or hemorrhagic
- You're evaluating for possible SBP in the setting of traumatic tap or hemorrhagic ascites
The 2009 Hepatology guidelines explicitly list hemorrhagic ascites as one of the conditions that can cause an elevated PMN count without true infection 3, 4, 3.
Critical Diagnostic Threshold
After correction, the diagnostic threshold for SBP remains:
- PMN ≥250 cells/mm³ warrants empiric antibiotic therapy 3, 1, 5
- This threshold has 100% sensitivity and 86% specificity for SBP diagnosis 2
Important Caveats
Do not skip the correction in hemorrhagic ascites. Without correction, you risk:
- Overdiagnosing SBP and unnecessarily treating with antibiotics
- Missing the true underlying cause of hemorrhagic ascites (malignancy, trauma, etc.)
Other causes of elevated PMN without infection that don't require this correction include 3, 4:
- Peritoneal carcinomatosis
- Pancreatitis
- Peritoneal tuberculosis
In malignancy-related ascites specifically, an RBC to total leukocyte ratio ≥100 and PMN to total leukocyte ratio ≤75% suggest malignancy rather than infection 2.
Clinical Application
The Korean Association for the Study of the Liver (KASL) 2018 guidelines provide the clearest statement on this correction 1, which aligns with the established practice described in multiple iterations of the American Association for the Study of Liver Diseases (AASLD) guidelines 3, 4, 3. This correction factor has been consistently used since at least 2004 and remains the standard approach.